Evgen Pharma PLC Collaboration with University of Michigan
13 June 2022 - 4:00PM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
13 June 2022
Evgen Pharma plc
("Evgen" or the "Company")
Collaboration with University of Michigan to evaluate SFX-01 in
models of colorectal cancer
Alderley Park, UK - 13 June 2022 : Evgen Pharma plc (AIM: EVG),
a clinical stage drug development company developing
sulforaphane-based medicines for the treatment of cancer and other
indications , announces a collaboration with Dr Grace Chen, of the
University of Michigan, to investigate the potential anti-tumour
effects of the Company's lead asset, SFX-01 in colorectal
cancer.
SFX-01 is a patented composition of synthetic sulforaphane and
alpha-cyclodextrin. Previous studies of the compound have shown in
vivo and in vitro efficacy of the compound in a wide range of
cancer cells including breast cancer, glioblastoma and certain
blood cancers.
The collaboration with the University of Michigan seeks to
evaluate the in vivo effects of SFX-01 in models of colorectal
cancer. The effects and mechanism of action of SFX-01 on organoid
growth, morphology, stemness and inflammatory markers will also be
investigated, using normal and malignant patient-derived organoids
and tumour tissue. Initial results are expected at the end of
2023.
Colorectal cancer is considered to be the third most common form
of cancer worldwide, with between 1.5-2 million annual diagnoses,
and second leading cause of cancer-related deaths. There has also
been an alarming global rise in early-onset colorectal cancer
occurring in individuals under 50 years of age. Treating colorectal
cancers can be difficult and does not always lead to cure
especially in advanced stages. Therefore, there is a strong need to
develop chemoprevention strategies as well as better treatment
options.
Dr Huw Jones, Evgen CEO, commented:
"This new project is our fifteenth pre-clinical collaboration to
date. Colorectal cancer is a relatively common disease and a cancer
type we have not explored extensively. The work of Dr. Chen's group
will gain valuable insights into the effects of SFX-01 in models of
colorectal cancer. Building on our existing promising data on the
mode of action, efficacy and tolerability of our lead asset, we
continue to develop our core products to address the widest
possible range of indications."
Dr Grace Chen, of the University of Michigan, lead investigator,
commented:
"We have seen the encouraging data of SFX-01 in various
indications and want to understand more about the potential of
Evgen's sulforaphane-synthetising technology in colorectal cancer
to help develop prevention strategies especially in high-risk
patients and improved treatment options for patients with advanced
colorectal cancer."
Evgen's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
Sulforaphanes have shown potential benefits in oncology by reducing
inflammation and blocking DNA mutation of cancer.
-Ends-
Enquiries:
Evgen Pharma plc Tel: +44 1625
Dr Huw Jones, CEO 466591
Richard Moulson, CFO
FinnCap (Nominated Advisor and Broker) Tel: +44 20 7220
Geoff Nash / Teddy Whiley (Corporate Finance) 0500
Alice Lane/Nigel Birks (ECM)
----------------------
Instinctif Partners Tel: +44 207 457
Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens 2020
/ Adam Loudon Evgen@Instinctif.com
----------------------
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer. It will be entering the clinic in glioma/glioblastoma later
in 2022. In September 2021 the FDA granted Orphan Drug status to
SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and AsiaPac as part of
the continuing strategy to build the data set of safety and
efficacy around the compound. With respect to non-core areas, Evgen
signed an outlicensing deal with JuvLife, the dietary products and
functional foods division of Juvenescence Ltd, for the development
of a naturally-sourced sulforaphane nutritional health supplement,
stabilised using Evgen's Sulforadex(R) technology.
The Company commenced operations in January 2008 and has its
headquarters and registered office at Alderley Park, Cheshire. It
joined the AIM market of the London Stock Exchange in October 2015
and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZGMVKZMGZZM
(END) Dow Jones Newswires
June 13, 2022 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024